Extended-release buprenorphine not cost-effective when transmucosal buprenorphine is available for treatment of OUD

Likelihood of experiencing a serious medical outcome or being admitted to a health care facility was increased for children younger than 6 years

Combination of a patch and fast-acting nicotine replacement therapy also effective

Among patients with ADRD receiving care from a home health agency, antipsychotic use was tied to less improvement in activities of daily living

Comparable rates of in-hospital adverse events seen among seniors prescribed oral antipsychotics after major surgery

Considerable impact scores reported in physical, psychological, social domains; professional lives also affected

Medications for OUD more likely for those with severe versus mild past-year OUD, receiving substance use treatment via telehealth

Significant improvement seen in 17-item Hamilton Depression Rating Scale, Clinical Global Impressions severity score

Improvement seen in measures of sleepiness, cataplexy over eight weeks versus placebo, but drug was associated with hepatotoxic effects

Pfizer is working to repair the damage and mitigate any shortage of drugs made at the facility